Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026)

Kura Oncology (KURA) has 3 years of Current Deferred Revenue data on file, last reported at $47.7 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $47.7 million, up 16.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.7 million (up 16.79% YoY), and the FY2025 annual result was $49.0 million, up 101.82% from the prior year.
• Current Deferred Revenue retreated to $47.7 million in Q1 2026 per KURA's latest filing, from $49.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $49.4 million in Q2 2025 and troughed at $24.3 million in Q4 2024.
• A 3-year average of $43.3 million and a median of $48.2 million in 2025 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue surged 101.82% in 2025, then rose 16.79% in 2026.
• A 3-year view of Current Deferred Revenue shows it stood at $24.3 million in 2024, then jumped by 101.82% to $49.0 million in 2025, then declined by 2.61% to $47.7 million in 2026.
• Business Quant data shows KURA's Current Deferred Revenue at $47.7 million in Q1 2026, $49.0 million in Q4 2025, and $48.8 million in Q3 2025.